Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy

@article{Evans2004PharmacogeneticsOT,
  title={Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy},
  author={William E. Evans},
  journal={Therapeutic Drug Monitoring},
  year={2004},
  volume={26},
  pages={186-191}
}
  • W. Evans
  • Published 1 April 2004
  • Biology, Medicine
  • Therapeutic Drug Monitoring
Abstract: Most medications exhibit wide interpatient variability in their efficacy and toxicity. For many medications, these interindividual differences result in part from polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, and/or drug targets (eg, receptors, enzymes). Pharmacogenomics is a burgeoning field aimed at elucidating the genetic basis of differences in drug efficacy and toxicity, using genome-wide approaches to identify the network of genes that govern an… 

Clinical pharmacology and pharmacogenetics of thiopurines

The recent advances in the knowledge of the mechanism of action as well as the molecular basis and interethnic variations of TPMT and inosine triphosphate pyrophosphatase are reviewed and an update on pharmacokinetics, metabolism, drug-drug interactions, safety, and tolerability of thiopurine drugs is provided.

PHARMACOGENOMIC RELATED TOXICITY OF 6-MERCAPTOPURINE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

This review highlights the current approaches to improve the clinical impact of 6-MP in childhood ALL in context with polymorphic TPMT gene with various rapid and inexpensive assays.

REVIEW PHARMACOGENOMIC RELATED TOXICITY OF 6-MERCAPTOPURINE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

This review highlights the current approaches to improve the clinical impact of 6-MP in childhood ALL in context with polymorphic TPMT gene with various rapid and inexpensive assays.

Preparing for the Genomic Age: Thiopurine S-Methytransferase Polymorphism

A case study of thiopurine s-methytransferase polymorphism is presented, providing insights into the mechanism of intolerance and offered strategies to avoid these toxicities.

Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.

  • T. M. Bosch
  • Biology, Medicine
    Methods in molecular biology
  • 2008
Evaluation of different regimens and tumor types showed that polymorphisms can have different, sometimes even contradictory, pharmacokinetic and pharmacodynamic effects in different tumors in response to different drugs.

Pharmacogenetics and immunosuppressive drugs in solid organ transplantation

The future of pharmacogenetics will be in treatment models in which patient characteristics are combined with data on polymorphisms in multiple genes, and these models should focus on pharmacodynamic parameters, variations in the expression of drug transporter proteins, and predictors of toxicity.

Pharmacodynamics Methyltransferase on Mercaptopurine and Thioguanine Differential Effects of Targeted Disruption of Thiopurine

The murine model recapitulates many clinical features of the human polymorphism; indicates that mercaptopurine is more affected by the TPMT polymorphism than thioguanine; and provides a preclinical system for establishing safer regimens of genetically influenced antileukemic drug therapy.

Pharmacogenetics in inflammatory bowel disease.

The variants in genes that influence either the efficacy or toxicity of common drugs used in the treatment of inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn's disease (CD) are described.

Pharma-Pharmacogenetics in inflammatory bowel disease

The variants in genes that influence either the efficacy or toxicity of common drugs used in the treatment of inflammatory bowel diseases (IBD), ulcerative colitis, and Crohn’s disease are described.

Azathioprine/6-mercaptopurine toxicity: The role of the TPMT gene

Clinicians should be aware that TPMT SNPs do not explain all leucopenic events and that T PMT measurements cannot replace the need for continued monitoring of leucocyte counts in AZA/6-MP treated patients.
...

References

SHOWING 1-10 OF 52 REFERENCES

Pharmacogenomics: the inherited basis for interindividual differences in drug response.

This chapter provides an overview of the current pharmacogenomics literature and offers insights for the potential impact of this field on the safe and effective use of medications.

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

It is concluded that genetic polymorphism in TPMT is an important determinant of mercaptopurine toxicity, even among patients who are heterozygous for this trait.

High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC.

DHPLC offers a highly sensitive, rapid, and efficient method for genotyping of the relevant TPMT mutations, discriminating at least for alleles *2 and *3, in clinical and laboratory practice.

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia

There are emerging data that TPMT genotype may influence the risk of secondary malignancies, including brain tumors and acute myelogenous leukemia, and ongoing studies aim to clarify the influence of T PMT on thiopurine efficacy, acute toxicity, and risk for delayed toxicity.

Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine

Patients received azathioprine, 2 to 3 mg/kg of body weight per day, as second-line therapy; some patients were also prescribed oral corticosteroids, and the hypothesis that molecular analysis of thiopurine methyltransferase may be a useful way to identify patients at risk for toxicity from thiopirine medication was proposed.

Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism.

Molecular cloning and structural characterization of the TPMT gene as well as elucidation of the molecular basis for a common T PMT genetic polymorphism will help make it possible to develop DNA-based diagnostic tests for the polymorphism and to determine the mechanism by which it results in decreased expression of this important drug-metabolizing enzyme.

Drug methylation in cancer therapy: lessons from the TPMT polymorphism

The genetic polymorphism of thiopurine methyltransferase (TPMT) is one of the most developed examples of pharmacogenetics, spanning from molecular genetics to clinical diagnostics for individualizing

Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

The segregation of RBC TPMT activity among 215 first-degree relatives in 50 randomly selected families and among 35 members of two kindreds and one family selected because they included probands with undetectable RBC enzyme activity were also compatible with the autosomal codominant inheritance of RBNT.

Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes.

The results were compatible with the conclusion that the genetic polymorphism which controls TPMT activity in the RBC also controls levels of this important enzyme activity in a major human drug metabolizing organ, the liver.
...